Abstract | OBJECTIVE: To explore the management of high-grade neuroendocrine cervical cancer (HGNECC) since there has been no standard treatment for it. METHODS: Data on the management of HGNECC were retrospectively analyzed. Patients with FIGO stage IIB to IVB HGNECC from six hospitals were enrolled. The Kaplan-Meier method was used for survival analysis. Prognostic factors were determined using a Cox proportional-hazards regression model. RESULTS: A total of 43 patients were included in the study. The multivariate analysis showed that chemotherapy was the preferred treatment as it improved progression-free survival (PFS; P = 0.008) and overall survival (OS; P = 0.005). Distance metastasis was a significant negative prognostic factor for OS (P = 0.002), while radical surgery was a significant positive prognostic factor for PFS (P = 0.05). Compared with those who had received cisplatin and etoposide (≥5 cycles), patients who had received paclitaxel plus platinum-based chemotherapy showed better PFS and OS. Five patients (two at stage IIB and three at stage IV) showed relatively long-term survival. Of these patients, four had undergone radical surgery including tumor-debulking, while three also received adjuvant chemotherapy. CONCLUSION:
|
Authors | Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu |
Journal | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
(Int J Gynaecol Obstet)
Vol. 158
Issue 3
Pg. 722-729
(Sep 2022)
ISSN: 1879-3479 [Electronic] United States |
PMID | 35124799
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | © 2022 International Federation of Gynecology and Obstetrics. |
Chemical References |
- Etoposide
- Carboplatin
- Paclitaxel
- Cisplatin
|
Topics |
- Carboplatin
(therapeutic use)
- Chemotherapy, Adjuvant
- Cisplatin
- Disease-Free Survival
- Etoposide
(therapeutic use)
- Female
- Humans
- Neoplasm Staging
- Paclitaxel
- Retrospective Studies
- Treatment Outcome
- Uterine Cervical Neoplasms
(pathology)
|